HRCT Thorax Report - Clinical Interpretation

Findings - Breakdown & Clinical Significance

1. Centrilobular and Paraseptal Emphysematous Changes - Bilateral Upper Lobes

• Centrilobular emphysema represents destruction of the respiratory bronchioles at the center of the secondary pulmonary lobule. On HRCT, it appears as focal areas of low attenuation ("punched-out" cystic spaces) with the centrilobular artery visible as a central "dot." It has a characteristic upper lobe predominance and is strongly associated with cigarette smoking.
• Paraseptal emphysema involves the distal acinar units along the pleural surfaces and interlobular septa, most commonly at the anterior/posterior upper lobes. It appears as thin-walled subpleural cysts/bullae along a single layer at the lung periphery.
• The co-existence of both types in a 61-year-old male strongly points to smoking-related COPD/emphysema as the underlying diagnosis. This directly explains the 3-month history of cough with expectoration.

2. Pleuroparenchymal Bands - Right Middle Lobe, Left Lingula, Right Posterobasal

• Pleuroparenchymal bands are linear opacities extending from the pleura into the lung parenchyma. They reflect fibrous scarring at the lung-pleura interface.
• Their presence in the right middle lobe, lingula, and right posterobasal segment suggests prior infection (e.g., resolved pneumonia/tuberculosis), aspiration injury, or early fibrotic change.
• These locations (lingula and right middle lobe) are typical sites of chronic aspiration or old healed inflammatory processes.
• In this clinical context (chronic cough + elderly smoker), these bands could also reflect a component of smoking-related parenchymal injury.

3. Mediastinal Lymphadenopathy - Largest Node 21x11mm in Subcarinal Region

• Subcarinal node 21x11mm - a short-axis diameter > 10mm is the standard CT threshold for pathological lymphadenopathy.
• Enlarged nodes were found in multiple stations: paratracheal, pre-vascular, bilateral hilar, and subcarinal - i.e., multi-station involvement.
• Bilateral hilar + mediastinal multi-station lymphadenopathy in a 61-year-old male with cough raises the following differential diagnoses (in order of priority given the clinical picture):

The combination of bilateral emphysema + bilateral hilar lymphadenopathy in a non-smoker would be classic for sarcoidosis - but in a heavy smoker with chronic cough, tuberculosis and malignancy must be actively excluded first.

4. No Mass Lesion, No Pleural/Pericardial Effusion, No Bronchiectasis

• Reassuring findings, but the absence of a visible mass on a non-contrast, motion-limited scan does not fully exclude a malignant etiology.
• No bronchiectasis or bronchial wall thickening - goes against a diagnosis of chronic suppurative lung disease.

5. Diffuse Osteopenia + Degenerative Vertebral Changes

• Age-related finding in a 61-year-old male; may reflect secondary osteoporosis (common in COPD due to corticosteroid use and systemic inflammation), or nutritional deficiency.
• Not directly related to the pulmonary complaints.

Impression Summary

Recommended Next Steps

1. Sputum workup: AFB smear and culture x3, Xpert MTB/RIF (GeneXpert) - to exclude active pulmonary TB
2. Contrast-enhanced CT Thorax - a non-contrast scan is limited; contrast will better characterize the lymph nodes (rim enhancement with central necrosis = TB; homogeneous enhancement = sarcoidosis/lymphoma)
3. Pulmonary Function Tests (PFT/Spirometry) - to quantify the degree of airflow obstruction from emphysema
4. Serum ACE level + serum calcium - elevated in sarcoidosis
5. CBNAAT/Bronchoscopy with BAL + EBUS-TBNA - to sample the subcarinal nodes (21mm) for histopathology if non-invasive workup is inconclusive
6. PET-CT - if malignancy is strongly suspected after the above
7. Bone mineral density (DEXA scan) - for the osteopenia

Key clinical note: The scan is labeled "Plain" (non-contrast) and there was a motion artifact limitation, making it a suboptimal study. The lymphadenopathy finding alone warrants a repeat contrast-enhanced CT for better evaluation before invasive procedures.

Updated Interpretation - With Smoking History

Calculating the Smoking Burden

• 25 beedis/day for 30 years
• Using a conservative 1:1 equivalence = 37.5 pack-years (minimum)
• Using 1 beedi = 2 cigarettes = 75 pack-year equivalent (more realistic)

This is a very heavy smoker by any standard. The USPSTF/NLST lung cancer screening threshold is 20 pack-years. This patient far exceeds it.

How the Smoking History Reframes Each Finding

Centrilobular + Paraseptal Emphysema

• Now fully explained - centrilobular emphysema is the hallmark of smoking-induced COPD, driven by neutrophil elastase-mediated alveolar destruction at the centrilobular level.
• Bilateral upper lobe predominance is exactly the expected pattern for smoking-related emphysema.
• With 30+ years of beedi smoking and 3 months of productive cough, this patient almost certainly has COPD (GOLD Stage to be determined by spirometry).

Pleuroparenchymal Bands

• In the context of heavy smoking, these may represent fibrotic changes from smoking-related interstitial lung changes or prior healed infection, both common in chronic beedi smokers in India.

The Most Important Reframing: Mediastinal Lymphadenopathy

Why Lung Cancer is the Top Priority to Exclude

• No mass lesion is mentioned - but this is a non-contrast plain CT with motion artifacts, meaning small endobronchial lesions, hilar masses, or mediastinal tumor extension can easily be missed.
• Beedi smokers have a higher relative risk of lung cancer than cigarette smokers, with squamous cell and small cell carcinoma being particularly linked to central airway involvement - which can present with lymphadenopathy without a visible parenchymal mass on a limited scan.
• Subcarinal node 21x11mm alone should trigger urgent oncologic workup.
• Chronic productive cough for 3 months in this context = new/change in cough symptom in a heavy smoker = red flag.

Revised Recommended Workup (Priority Order)

1. URGENT: Contrast-Enhanced CT Thorax + Upper Abdomen
   • Better characterize the mediastinal nodes
   • Look for endobronchial lesions, hilar masses, or pleural involvement missed on this limited plain scan
   • Assess upper abdomen for liver/adrenal metastases
2. Sputum Cytology x3 - for malignant cells (easy, cheap, non-invasive first step)
3. Sputum AFB smear + Culture + GeneXpert - simultaneously rule out TB
4. Bronchoscopy with BAL + Endobronchial Ultrasound (EBUS-TBNA)
   • Direct sampling of the enlarged subcarinal node (21mm - easily accessible by EBUS)
   • Tissue diagnosis is mandatory before any treatment
5. Spirometry/PFTs - quantify COPD severity (will also influence treatment planning if malignancy is confirmed)
6. Serum LDH, CBC with differential, serum calcium, ACE level - baseline labs and to help differentiate lymphoma vs. sarcoidosis
7. PET-CT - if CECT and bronchoscopy suggest malignancy, PET-CT to fully stage the disease

Bottom Line